Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 178

1.

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM.

J Infect Dis. 2005 Apr 15;191(8):1210-5. Epub 2005 Mar 14.

PMID:
15776364
[PubMed - indexed for MEDLINE]
Free Article
2.

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC.

Lancet. 2001 Jun 16;357(9272):1937-43.

PMID:
11425416
[PubMed - indexed for MEDLINE]
3.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.

PMID:
20371470
[PubMed - indexed for MEDLINE]
Free Article
4.

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.

Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M.

Vaccine. 2003 Apr 2;21(15):1687-93.

PMID:
12639491
[PubMed - indexed for MEDLINE]
5.

Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.

Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI.

Vaccine. 2006 Nov 17;24(47-48):6859-66. Epub 2006 Jun 28.

PMID:
17050041
[PubMed - indexed for MEDLINE]
6.

Evaluation of a positive marker of avian influenza vaccination in ducks for use in H5N1 surveillance.

James CM, Foong YY, Mansfield JP, Vind AR, Fenwick SG, Ellis TM.

Vaccine. 2008 Oct 3;26(42):5345-51. doi: 10.1016/j.vaccine.2008.08.008. Epub 2008 Aug 22.

PMID:
18723069
[PubMed - indexed for MEDLINE]
7.

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.

Clin Infect Dis. 2009 Apr 15;48(8):1087-95. doi: 10.1086/597401.

PMID:
19281330
[PubMed - indexed for MEDLINE]
Free Article
8.

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB.

Clin Infect Dis. 2006 Nov 1;43(9):1135-42. Epub 2006 Sep 25.

PMID:
17029131
[PubMed - indexed for MEDLINE]
Free Article
9.

Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia.

Isoda N, Sakoda Y, Kishida N, Soda K, Sakabe S, Sakamoto R, Imamura T, Sakaguchi M, Sasaki T, Kokumai N, Ohgitani T, Saijo K, Sawata A, Hagiwara J, Lin Z, Kida H.

Arch Virol. 2008;153(9):1685-92. doi: 10.1007/s00705-008-0171-1. Epub 2008 Jul 25.

PMID:
18651092
[PubMed - indexed for MEDLINE]
10.

The immunogenicity and efficacy against H5N1 challenge of reverse genetics-derived H5N3 influenza vaccine in ducks and chickens.

Webster RG, Webby RJ, Hoffmann E, Rodenberg J, Kumar M, Chu HJ, Seiler P, Krauss S, Songserm T.

Virology. 2006 Aug 1;351(2):303-11. Epub 2006 May 11.

PMID:
16690097
[PubMed - indexed for MEDLINE]
Free Article
11.

Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.

Jadhao SJ, Lee CW, Sylte M, Suarez DL.

Vaccine. 2009 Oct 19;27(44):6247-60. doi: 10.1016/j.vaccine.2009.07.110. Epub 2009 Aug 15.

PMID:
19686695
[PubMed - indexed for MEDLINE]
12.

Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.

Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J.

Vaccine. 2008 Jul 4;26(29-30):3640-6. doi: 10.1016/j.vaccine.2008.04.071. Epub 2008 May 15.

PMID:
18514980
[PubMed - indexed for MEDLINE]
13.

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.

Vaccine. 2008 Nov 25;26(50):6383-91. doi: 10.1016/j.vaccine.2008.08.046. Epub 2008 Sep 16.

PMID:
18801398
[PubMed - indexed for MEDLINE]
14.

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, Gillard P, Jilg W.

Vaccine. 2009 Oct 23;27(45):6284-90.

PMID:
19856521
[PubMed - indexed for MEDLINE]
15.

Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.

Römer-Oberdörfer A, Veits J, Helferich D, Mettenleiter TC.

Vaccine. 2008 May 2;26(19):2307-13. doi: 10.1016/j.vaccine.2008.02.061. Epub 2008 Mar 18.

PMID:
18395947
[PubMed - indexed for MEDLINE]
16.

Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine.

Philippa J, Baas C, Beyer W, Bestebroer T, Fouchier R, Smith D, Schaftenaar W, Osterhaus A.

Vaccine. 2007 May 10;25(19):3800-8. Epub 2007 Feb 26.

PMID:
17403559
[PubMed - indexed for MEDLINE]
17.

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I.

J Infect Dis. 2008 Sep 1;198(5):642-9. doi: 10.1086/590913.

PMID:
18576945
[PubMed - indexed for MEDLINE]
Free Article
18.

Efficacy of a commercial inactivated H5 influenza vaccine against highly pathogenic avian influenza H5N1 in waterfowl evaluated under field conditions.

Rudolf M, Pöppel M, Fröhlich A, Mettenleiter T, Beer M, Harder T.

Rev Sci Tech. 2009 Apr;28(1):275-91.

PMID:
19618632
[PubMed - indexed for MEDLINE]
19.

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7. doi: 10.1073/pnas.0903181106. Epub 2009 Apr 27.

PMID:
19416838
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ.

J Infect Dis. 2008 Sep 1;198(5):635-41. doi: 10.1086/590916.

PMID:
18694338
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk